


IMPAX LABORATORIES, INC.,)
 ASTRAZENECA AB, and)
 ASTRAZENECA UK LIMITED,)
) C.A. No. 14-984-RGA
 Plaintiffs,) (Consolidated)
)
 v.)
)
 LANNETT HOLDINGS, INC. and)
 LANNETT COMPANY, INC.,)
)
 Defendants.)
)


For the reasons stated in its Oral Order of November 16, 2015 (*see* D.I. 59), and its Memorandum Opinion issued December 1, 2015 (D.I. 60), the Court has determined that the following terms used in the asserted claims of U.S. Patent Nos. 6,750,237 (“the ’237 patent”) and 7,220,767 (“the ’767 patent”) have the following meanings:

{01068034;v1 }

Further, the parties previously agreed in the Joint Claim Construction Brief filed September 23, 2015 (D.I. 49), that the following terms used in the asserted claims of the '237 and '767 patents have the following meanings, which constructions the Court hereby adopts:

Claim Term	Agreed Construction
"disodium phosphate"	Compounds containing the basic structure as depicted in Figure 2 below, including all forms thereof, including sodium hydrogen phosphate; disodium hydrogen orthophosphate; sodium phosphate dibasic; dibasic sodium phosphate; disodium phosphate dodecahydrate; disodium phosphate heptahydrate; disodium phosphate dihydrate; and anhydrous disodium phosphate.  Figure 2
"pH of the formulation is 5"	The pH is 5 +/- 0.04.

SO ORDERED this 7 day of December, 2015.


 United States District Court Judge